Clinical trials: Zoledronic acid, completed
Osteoporosis
Denosumab Sequential Therapy
Denosumab is a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis. Although denosumab has excellent effect to increase bone mass and prevent fracture in FREEDOM study with very low complications…
- Trial name
- DST (NCT03868033)
- Testing
- Zoledronic Acid, Denosumab
- Where
- Taiwan
- Volunteers
- 101 people
- Sponsor
- National Taiwan University Hospital
Bone Metastases
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer
- Trial name
- NCT00321620
- Testing
- zoledronic acid, denosumab
- Volunteers
- 1,904 people
- Sponsor
- Amgen
Risk Factors for or a Diagnosis of Osteoporosis
Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone
The purpose of this study is to determine the maximum tolerated concentration (MTC) of bisphosphonate with a fixed dose of rHuPH20 administered SC, the MTC of bisphosphonate without rHuPH20 administered SC, the optimal dose of…
- Trial name
- NCT00807963
- Testing
- rHuPH20, zoledronic acid
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Halozyme Therapeutics
Non-Small-Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
30-40% of patients with lung cancer will develop bone metastases during the course of their disease, which can lead to pain, decreased mobility and skeletal complications.
- Trial name
- NCT00172042
- Testing
- Zoledronic acid 4 mg
- Where
- 69 sites in Belgium, China and 13 more
- Volunteers
- 437 people
- Sponsor
- Novartis Pharmaceuticals
Bone Loss, Prostate Cancer
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
The primary objective of this study is to determine whether zoledronic acid (Zometa) given once annually increases bone mineral density in men receiving hormone therapy for prostate cancer.
- Trial name
- NCT00181584
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Post-Menopausal Osteoporosis
Intra-venous Zoledronic Acid Once Yearly
The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment.
- Trial name
- IVORY (NCT00984893)
- Testing
- zoledronic acid, Any oral bisphosphonates marketed in Canada
- Where
- 3 sites in Canada
- Volunteers
- 1,551 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate or thalidomide and Zometa is in controlling the myeloma disease and to study any side effects.
- Trial name
- NCT00083382
- Testing
- Pamidronate, Thalidomide, Zometa
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- University of Arkansas
Crohn's Disease, Osteopenia
Zoledronate for Osteopenia in Pediatric Crohn's
Background: Up to 30% of children and adolescents with Crohn's disease have decreased bone strength, or decrease bone density, called osteopenia.
- Conditions
- Crohn's Disease, Osteopenia, Osteoporosis
- Trial name
- NCT00798473
- Testing
- zoledronic acid, IV saline infusion
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Breast Cancer, Prostate Cancer
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
The current Rethinking Clinical Trials (REaCT) trial will compare two schedules(12- vs. 4-weekly) of bone-targeting agents (BTAs) to evaluate quality of life, pain and skeletal events within the Canadian Health Care System.
- Conditions
- Breast Cancer, Prostate Cancer, Metastasis
- Trial name
- REaCT-BTA (NCT02721433)
- Testing
- Pamidronate, Denosumab, Zoledronate
- Where
- Canada
- Volunteers
- 263 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer
Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis
The purpose of this research study is to evaluate the usefulness of the TRAP protein as (1) an early indicator of bone destruction and (2) a tool for assessing the effect of Zometa® in treating symptoms of bone metastases due to…
- Trial name
- NCT00264082
- Testing
- Zometa(drug)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Louisville
Multiple Myeloma
Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
The aim of this study is to evaluate the effect of bortezomib in combination with dexamethasone and zoledronic acid on bone mineral density (BMD) and skeletal related events (SREs) in Patients with Multiple Myeloma who Have…
- Trial name
- NCT00972959
- Testing
- Bortezomib, Zoledronic Acid, Dexamethasone
- Where
- 3 sites in Greece
- Volunteers
- 17 people
- Sponsor
- University of Athens
Locally Advanced Breast Cancer, Ductal Histologic Type
Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers
Breast cancer is the leading female cancer by a very wide margin in France. Despite widespread breast cancer screening, many cases of breast cancer are discovered at a locally advanced stage.
- Conditions
- Locally Advanced Breast Cancer, Ductal Histologic Type, Without Her 2 Overexpression
- Trial name
- NEOZOL (NCT01367288)
- Testing
- Zometa + Neoadjuvant therapy, Neoadjuvant therapy
- Where
- France
- Volunteers
- 53 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer
Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy
The purpose of this study is to determine the event-free survival (EFS) after zoledronic acid for 5 years versus no postoperative treatment in patients with "chemo-insensitive" breast cancer (ypT1-4 and/or ypN1-3) after…
- Trial name
- NATAN (NCT00512993)
- Testing
- Zoledronic acid
- Where
- 93 sites in Austria, Germany
- Volunteers
- 654 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer, Osteoporosis
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss.
- Trial name
- NCT00022087
- Testing
- calcium salts, cholecalciferol, zoledronic acid
- Where
- 107 sites in United States
- Volunteers
- 439 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Osteoporosis
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00107263
- Testing
- letrozole, zoledronic acid
- Volunteers
- 558 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Postmenopausal Osteoporosis
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide.
- Trial name
- DATA-HD (NCT02176382)
- Testing
- denosumab, teriparatide, Zoledronic acid
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Post-menopausal Osteoporosis
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
- Trial name
- NCT00718861
- Testing
- Zoledronic acid
- Where
- 57 sites in United States, Argentina and 16 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
This study examines the safety and efficacy of zoledronic acid 4 mg., given every 3 months over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18 and 21) in improving bone mineral density in premenopausal women with hormone…
- Trial name
- NCT00375505
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Osteoporosis
Atorvastatin (Lipitor) to Prevent Bone Pain
In the proposed randomized double blind cross-over placebo controlled study, the researchers intend to investigate if Atorvastatin (FDA approved statin for children) can be used to alleviate the symptom of bone pain (acute phase…
- Trial name
- NCT00120133
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Mercy Hospital Kansas City